Cargando…
Linagliptin as add-on therapy to insulin for patients with type 2 diabetes
Type 2 diabetes mellitus (T2DM) is a highly prevalent, progressive disease that often is poorly controlled. The combination of an incretin-based therapy and insulin is a promising approach to optimize the management of glycemic control without hypoglycemia and weight gain. Linagliptin, a recently ap...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818026/ https://www.ncbi.nlm.nih.gov/pubmed/24204157 http://dx.doi.org/10.2147/VHRM.S40035 |
_version_ | 1782478146310766592 |
---|---|
author | von Websky, Karoline Reichetzeder, Christoph Hocher, Berthold |
author_facet | von Websky, Karoline Reichetzeder, Christoph Hocher, Berthold |
author_sort | von Websky, Karoline |
collection | PubMed |
description | Type 2 diabetes mellitus (T2DM) is a highly prevalent, progressive disease that often is poorly controlled. The combination of an incretin-based therapy and insulin is a promising approach to optimize the management of glycemic control without hypoglycemia and weight gain. Linagliptin, a recently approved oral dipeptidyl peptidase-4 inhibitor, has a unique pharmacological profile. The convenient, once-daily dosing does not need adjustment in patients with hepatic and/or renal impairment. In clinical studies linagliptin shows an important reduction of blood glucose with an overall safety profile similar to that of placebo. So far, the combination of linagliptin and insulin has been tested in three major clinical studies in different populations. It has been shown that linagliptin is an effective and safe add-on therapy to insulin in patients with T2DM. The efficacy and safety of this combination was also shown in vulnerable, elderly T2DM patients and in patients with T2DM and renal impairment. Favorable effects regarding the counteraction of hypoglycemia make linagliptin especially interesting as an add-on therapy to insulin. This review aims to present the existing clinical studies on the efficacy and safety of linagliptin as add-on therapy to insulin in patients with T2DM in the context of current literature. Additionally, the possible advantages of linagliptin as an add-on therapy to insulin in relation to cardiovascular safety, patient-centered therapy and the prevention of hypoglycemia, are discussed. |
format | Online Article Text |
id | pubmed-3818026 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-38180262013-11-07 Linagliptin as add-on therapy to insulin for patients with type 2 diabetes von Websky, Karoline Reichetzeder, Christoph Hocher, Berthold Vasc Health Risk Manag Review Type 2 diabetes mellitus (T2DM) is a highly prevalent, progressive disease that often is poorly controlled. The combination of an incretin-based therapy and insulin is a promising approach to optimize the management of glycemic control without hypoglycemia and weight gain. Linagliptin, a recently approved oral dipeptidyl peptidase-4 inhibitor, has a unique pharmacological profile. The convenient, once-daily dosing does not need adjustment in patients with hepatic and/or renal impairment. In clinical studies linagliptin shows an important reduction of blood glucose with an overall safety profile similar to that of placebo. So far, the combination of linagliptin and insulin has been tested in three major clinical studies in different populations. It has been shown that linagliptin is an effective and safe add-on therapy to insulin in patients with T2DM. The efficacy and safety of this combination was also shown in vulnerable, elderly T2DM patients and in patients with T2DM and renal impairment. Favorable effects regarding the counteraction of hypoglycemia make linagliptin especially interesting as an add-on therapy to insulin. This review aims to present the existing clinical studies on the efficacy and safety of linagliptin as add-on therapy to insulin in patients with T2DM in the context of current literature. Additionally, the possible advantages of linagliptin as an add-on therapy to insulin in relation to cardiovascular safety, patient-centered therapy and the prevention of hypoglycemia, are discussed. Dove Medical Press 2013 2013-11-01 /pmc/articles/PMC3818026/ /pubmed/24204157 http://dx.doi.org/10.2147/VHRM.S40035 Text en © 2013 von Websky et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Review von Websky, Karoline Reichetzeder, Christoph Hocher, Berthold Linagliptin as add-on therapy to insulin for patients with type 2 diabetes |
title | Linagliptin as add-on therapy to insulin for patients with type 2 diabetes |
title_full | Linagliptin as add-on therapy to insulin for patients with type 2 diabetes |
title_fullStr | Linagliptin as add-on therapy to insulin for patients with type 2 diabetes |
title_full_unstemmed | Linagliptin as add-on therapy to insulin for patients with type 2 diabetes |
title_short | Linagliptin as add-on therapy to insulin for patients with type 2 diabetes |
title_sort | linagliptin as add-on therapy to insulin for patients with type 2 diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3818026/ https://www.ncbi.nlm.nih.gov/pubmed/24204157 http://dx.doi.org/10.2147/VHRM.S40035 |
work_keys_str_mv | AT vonwebskykaroline linagliptinasaddontherapytoinsulinforpatientswithtype2diabetes AT reichetzederchristoph linagliptinasaddontherapytoinsulinforpatientswithtype2diabetes AT hocherberthold linagliptinasaddontherapytoinsulinforpatientswithtype2diabetes |